98,727 Shares in The Oncology Institute, Inc. $TOI Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP acquired a new stake in shares of The Oncology Institute, Inc. (NASDAQ:TOI) in the second quarter, Holdings Channel reports. The firm acquired 98,727 shares of the company’s stock, valued at approximately $536,000.

Several other hedge funds have also added to or reduced their stakes in the stock. Josh Arnold Investment Consultant LLC raised its position in shares of Oncology Institute by 1,104.3% in the 4th quarter. Josh Arnold Investment Consultant LLC now owns 2,459,809 shares of the company’s stock worth $8,757,000 after purchasing an additional 2,255,559 shares during the last quarter. GatePass Capital LLC bought a new stake in Oncology Institute during the 4th quarter valued at about $1,282,000. Arrowstreet Capital Limited Partnership raised its holdings in Oncology Institute by 169.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 419,423 shares of the company’s stock worth $1,288,000 after buying an additional 263,699 shares during the last quarter. FourWorld Capital Management LLC lifted its stake in shares of Oncology Institute by 30.4% in the first quarter. FourWorld Capital Management LLC now owns 499,196 shares of the company’s stock worth $1,533,000 after buying an additional 116,496 shares in the last quarter. Finally, T3 Companies LLC bought a new stake in shares of Oncology Institute during the fourth quarter valued at approximately $716,000. 36.86% of the stock is owned by institutional investors.

Oncology Institute Price Performance

Shares of Oncology Institute stock opened at $5.19 on Friday. The Oncology Institute, Inc. has a 1-year low of $2.32 and a 1-year high of $6.67. The company’s fifty day simple moving average is $5.31 and its 200-day simple moving average is $4.10. The stock has a market capitalization of $512.58 million, a PE ratio of -14.02 and a beta of 0.39.

Oncology Institute (NASDAQ:TOI) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $161.28 million during the quarter, compared to analysts’ expectations of $155.28 million. As a group, research analysts anticipate that The Oncology Institute, Inc. will post -0.18 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have commented on TOI. Lake Street Capital assumed coverage on Oncology Institute in a report on Monday, July 6th. They issued a “buy” rating and a $10.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncology Institute in a research note on Friday, July 17th. BTIG Research increased their price objective on shares of Oncology Institute from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. Finally, Needham & Company LLC boosted their target price on shares of Oncology Institute from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Wednesday, June 17th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Oncology Institute presently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

Insider Transactions at Oncology Institute

In other news, insider Yale Podnos sold 23,451 shares of the firm’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $5.38, for a total value of $126,166.38. Following the transaction, the insider owned 259,527 shares of the company’s stock, valued at $1,396,255.26. This trade represents a 8.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett acquired 18,000 shares of the stock in a transaction dated Tuesday, July 21st. The shares were bought at an average cost of $5.27 per share, for a total transaction of $94,860.00. Following the completion of the transaction, the insider owned 10,648,858 shares in the company, valued at approximately $56,119,481.66. This represents a 0.17% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders acquired 63,000 shares of company stock valued at $329,970. Company insiders own 4.40% of the company’s stock.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.